Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Dermatofibrosarcoma × pazopanib × Clear all

Phase

Phase 2/3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 22 Sarcoma 14 Neoplasm Metastasis 10 Carcinoma, Non-Small-Cell Lung 8 Breast Neoplasms 8 Ovarian Neoplasms 6 Recurrence 5 Neoplasms 5 Melanoma 4 Leiomyosarcoma 4 Urinary Bladder Neoplasms 3 Neuroendocrine Tumors 3 Lung Neoplasms 3 Liposarcoma 3 Hemangiosarcoma 3 Glioblastoma 3 Gastrointestinal Stromal Tumors 3 Fallopian Tube Neoplasms 3 Uterine Cervical Neoplasms 2 Thyroid Neoplasms 2 Small Cell Lung Carcinoma 2 Sarcoma, Synovial 2 Sarcoma, Alveolar Soft Part 2 Rhabdomyosarcoma 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Osteosarcoma 2 Kidney Neoplasms 2 Gliosarcoma 2 Clear-cell metastatic renal cell carcinoma 2

Interventions

Imatinib Mesylate 4 Gemcitabine 2 Doxorubicin 2 Docetaxel 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 saracatinib 1 pembrolizumab 1 pazopanib 1 envafolimab 1 TTI-621 1 Sunitinib 1 Razoxane 1 Radiotherapy, Intensity-Modulated 1 Radiation Dose Hypofractionation 1 Quality of Life 1 Polymerase Chain Reaction 1 Neoadjuvant Therapy 1 MLN 8237 1 Ipilimumab 1 Gene Expression Profiling 1 Dexrazoxane 1 Dactinomycin 1 Blotting, Western 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01059656 2016-07-01

DFSP-PAZO

Assistance Publique - Hôpitaux de Paris

Phase 2 Terminated

Dermatofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡